Key result
Angiotensin converting enzyme inhibitors were associated with increased mortality in Alzheimer's disease compared to other antihypertensives (HR 1.19; 95% CI 1.07-1.33; p=0.002).
Why the study?
Do angiotensin II receptor blockers or angiotensin converting enzyme inhibitors affect mortality or hospitalization in patients with dementia compared to other antihypertensive medications?
Cohort (n=6,290)
Do angiotensin II receptor blockers or angiotensin converting enzyme inhibitors affect mortality or hospitalization in patients with dementia compared to other antihypertensive medications?
Angiotensin converting enzyme inhibitors may be associated with an increased risk of mortality in patients with Alzheimer's disease compared to other antihypertensives, warranting further investigation.
We investigated whether angiotensin II receptor blockers and angiotensin converting enzyme inhibitors were associated with risk of mortality or inpatient hospitalization for patients with dementia compared to other antihypertensive medications. We extracted a clinical cohort of 6,290 patients with dementia from the United Kingdom General Practice Research Database, prescribed antihypertensive medication at diagnosis of dementia with around 10 years follow-up. Using survival analysis we estimated associations of exposure to antihypertensive medication with subsequent hospitalization and mortality risk, stratified by dementia type (Alzheimer's disease, vascular and other dementias). Angiotensin converting enzyme inhibitors (but not angiotensin II receptor blockers) were associated with an increased risk of mortality in patients with Alzheimer's disease (adjusted hazard ratio: 1.19; 95% CI 1.07, 1.33, p = 0.002), but no convincing evidence of increased hospitalization. Angiotensin II receptor blockers were inversely associated with hospitalization for any form of dementia, but after adjustment for covariates, these associations became consistent with chance. Further evidence is required to either support or refute the observation that exposure to angiotensin converting enzyme inhibitors in patients with dementia is associated with increased mortality.
No takes yet. Share an insight, caveat, or question.
Kehoe et al. (2013) conducted a cohort in Dementia (n=6,290). Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers vs. Other antihypertensive medications was evaluated on Mortality or inpatient hospitalization (HR 1.19, 95% CI 1.07-1.33, p=0.002). Angiotensin converting enzyme inhibitors were associated with increased mortality in Alzheimer's disease compared to other antihypertensives (HR 1.19; 95% CI 1.07-1.33; p=0.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: